Laryngo-rhino-otologiePub Date : 2024-10-01Epub Date: 2024-09-03DOI: 10.1055/a-2251-0658
Helen Heppt, Charles Schmit, Veronika Innerhofer, Timo Gottfried, Verena Strasser, Benedikt Hofauer, Daniel Dejaco
{"title":"[Ultrasound - part 4: sonography of neck lymph nodes].","authors":"Helen Heppt, Charles Schmit, Veronika Innerhofer, Timo Gottfried, Verena Strasser, Benedikt Hofauer, Daniel Dejaco","doi":"10.1055/a-2251-0658","DOIUrl":"10.1055/a-2251-0658","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"701-704"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laryngo-rhino-otologiePub Date : 2024-10-01Epub Date: 2023-08-29DOI: 10.1055/a-2119-7652
Luciano Accetta, Hanna Spielmann, Eckart Bertelmann
{"title":"[Orbital lesion as the initial manifestation of a neuroendocrine tumour].","authors":"Luciano Accetta, Hanna Spielmann, Eckart Bertelmann","doi":"10.1055/a-2119-7652","DOIUrl":"10.1055/a-2119-7652","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"728-731"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10113238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laryngo-rhino-otologiePub Date : 2024-10-01Epub Date: 2024-07-04DOI: 10.1055/a-2214-1669
Viktoria Schindler, Nils Venhoff
{"title":"[Eosinophilic granulomatosis with polyangiitis: a review article].","authors":"Viktoria Schindler, Nils Venhoff","doi":"10.1055/a-2214-1669","DOIUrl":"10.1055/a-2214-1669","url":null,"abstract":"<p><p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare form of ANCA-associated vasculitis (AAV) within the group of small vessel vasculitides. It is defined by vasculitis of small and medium-sized vessels with granulomatous inflammation and blood and tissue eosinophilia. Almost all patients have allergic symptoms with bronchial asthma and rhinosinusitis symptoms. Further clinical manifestations vary depending on the localisation, severity, and type of disease manifestation. Eosinophilic infiltration and inflammation may result in rhinosinusitis, pneumonitis, gastrointestinal involvement, and cardiomyopathy. The latter, in particular, is associated with a poorer prognosis. As a necrotising pauci-immune small-vessel vasculitis, EGPA, similar to the other AAVs, can cause pulmonary infiltrates with alveolar haemorrhage, glomerulonephritis, cutaneous vasculitis with purpura as well as central and peripheral neurologic injuries. The presence of perinuclear ANCA (pANCA) with specificity against myeloperoxidase (MPO) is observed in approximately one-third of patients but is not specific to EGPA. MPO-ANCA-positive patients are more likely to have peripheral neurologic involvement and glomerulonephritis, whereas ANCA-negative patients are more likely to have cardiac and pulmonary involvement. What is frequently challenging in the clinical routine is to differentiate EGPA from the hypereosinophilic syndrome (HES). The therapeutic approach to EGPA depends on whether the severity of the disease is potentially organ or life-threatening. For severe forms of EGPA, acute therapy mainly includes glucocorticoids in combination with cyclophosphamide. Rituximab has come to be mentioned as an alternative treatment option in the guidelines. Various immunosuppressive therapies are available for remission maintenance. In EGPA without severe organ involvement, IL-5 blockade with mepolizumab is an approved treatment.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"705-714"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141534747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eingriffe an Larynx, Hypopharynx und Trachea.","authors":"J A Werner, J P Windfuhr","doi":"10.1055/a-2347-7821","DOIUrl":"10.1055/a-2347-7821","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":"103 10","pages":"757-760"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andreas Dietz, Matthäus Stöhr, Veit Zebralla, Markus Pirlich, Susanne Wiegand, Nils H Nicolay
{"title":"[Surgical Treatment of Hypopharyngeal Carcinoma, Neck Dissection and Adjuvant Postoperative Therapy of Oropharyngeal and Hypopharyngeal Cancer: Recommendations of the current S3 Guideline - Part II].","authors":"Andreas Dietz, Matthäus Stöhr, Veit Zebralla, Markus Pirlich, Susanne Wiegand, Nils H Nicolay","doi":"10.1055/a-2223-4098","DOIUrl":"https://doi.org/10.1055/a-2223-4098","url":null,"abstract":"<p><p>Part II of the S3 guideline report deals with the surgical treatment of hypopharyngeal carcinoma, neck dissection for oropharyngeal and hypopharyngeal carcinomas and adjuvant therapy options. Primary surgical therapy ± adjuvant radio- or radiochemotherapy and primary radio- or radiochemotherapy are established as primary therapies for local-regional hypopharyngeal carcinomas. Direct randomized comparisons of both basic therapeutic procedures were never conducted. Available registry data show a worse prognosis of hypopharyngeal carcinoma compared to oropharyngeal carcinomas in all locoregional tumor stages, regardless of the treatment method. For T1N0-T2N0 squamous cell carcinoma of the hypopharynx, there are no relevant differences in overall survival and locoregional relapse rate between primary surgical and primary non-surgical treatment. Primary surgical therapy ± adjuvant radiotherapy or radiochemotherapy and primary radiotherapy or radiochemotherapy are established as primary therapies for advanced but locoregionally limited hypopharyngeal carcinomas. Neck dissection is an integral part of the primary surgical treatment of oropharyngeal and hypopharyngeal cancer. There are only a few randomized studies on non-surgical organ preservation for advanced hypopharyngeal cancer as an alternative to pharyngolaryngectomy, but these have led to the recommendation of alternative concepts in the new guideline. The indication and implementation of postoperative adjuvant radiotherapy and radiochemotherapy for hypopharyngeal carcinoma do not differ from those for HPV/p16-negative and -positive oropharyngeal carcinoma.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":"103 10","pages":"734-753"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Kommentar zu „Nasopharynxkarzinom: künstliche Intelligenz zur Prognosebestimmung“.","authors":"","doi":"10.1055/a-2359-5657","DOIUrl":"https://doi.org/10.1055/a-2359-5657","url":null,"abstract":"","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":"103 10","pages":"696-697"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142365746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laryngo-rhino-otologiePub Date : 2024-10-01Epub Date: 2024-05-16DOI: 10.1055/a-2306-2702
Michaela Maria Plath, Matthias Sand, Mark-Philip Gruchlik, Carlo Cavaliere, Sara Friauf, Peter Plinkert, Karim Plath, Ingo Baumann
{"title":"[Short-term quality of life assessment after sinus surgery for chronic rhinosinusitis].","authors":"Michaela Maria Plath, Matthias Sand, Mark-Philip Gruchlik, Carlo Cavaliere, Sara Friauf, Peter Plinkert, Karim Plath, Ingo Baumann","doi":"10.1055/a-2306-2702","DOIUrl":"10.1055/a-2306-2702","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis (CRS) has a negative impact on health-related quality of life (HRQoL). Functional endoscopic sinus surgery (FESS) is the treatment of choice for those not responding to medical treatments. To date, the short-term effects of FESS on HRQoL are still unclear.</p><p><strong>Objective: </strong>Evaluation of the short-term effects of FESS on HRQoL in CRS patients using the SNOT-22 questionnaire.</p><p><strong>Methods: </strong>The results of the validated German version of the Sino-Nasal Outcome Test-22 (SNOT-22) questionnaire were analysed from 89 patients with CRS before surgery and 10-14 days (n = 77), four (n = 77), six weeks (n = 76) and 6 months (n = 71) after FESS, and compared with those of 1,000 healthy controls selected using a non-probability quota sample in accordance to the distribution of the German Microcensus.</p><p><strong>Results: </strong>Compared to the preoperative mean SNOT-22 score (47.35), CRS patients significantly improved in HRQoL 10-14 days (31.75, p < 0.01), 4 weeks (25.84, p < 0.01), 6 weeks (24.16, p < 0.01) and 6 months after FESS (27.16, p < 0.01). Pre- and 6 months postoperatively, the five most important SNOT-22 items were nasal obstruction, smell and taste reduction, thick, mucous nasal secretions, need to blow the nose and postnasal drip. At the 2, 4 and 6-week follow-up, the reduction in smell and taste was most frequently perceived as limiting the HRQoL.</p><p><strong>Conclusions: </strong>This follow-up study shows for the first time that the reduction in smell and taste should be treated and controlled concervatively in the short term after FESS.</p>","PeriodicalId":17965,"journal":{"name":"Laryngo-rhino-otologie","volume":" ","pages":"715-722"},"PeriodicalIF":0.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140957555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}